At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRDF Cardiff Oncology, Inc.
Pre-Mkt 01-27 06:59:46 EST
2.94
+0.04
+1.38%
High2.96Low2.80Vol617.08K
Open2.88D1 Closing2.90Amplitude5.21%
Mkt Cap198.04MTradable Cap193.25MTotal Shares67.36M
T/O1.79MT/O Rate0.94%Tradable Shares65.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cardiff Oncology Announces New Clinical Data on Onvansertib in Chronic Myelomonocytic Leukemia
Reuters  ·  2025-12-09
Cardiff Oncology Announces New Clinical Data on Onvansertib in Chronic Myelomonocytic Leukemia
Cardiff Oncology Announces Clinical Data From Investigator-Sponsored Trial With Onvansertib in Chronic Myelomonocytic Leukemia at Ash 2025
THOMSON REUTERS  ·  2025-12-09
Cardiff Oncology Announces Clinical Data From Investigator-Sponsored Trial With Onvansertib in Chronic Myelomonocytic Leukemia at Ash 2025
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
Reuters  ·  2025-12-08
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference
Cardiff Oncology to Present at Piper Sandler Healthcare Conference
Reuters  ·  2025-11-24
Cardiff Oncology to Present at Piper Sandler Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), BioLife Solutions (BLFS) and Cardiff Oncology (CRDF)
TIPRANKS  ·  2025-11-11
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), BioLife Solutions (BLFS) and Cardiff Oncology (CRDF)
Analysts Are Bullish on These Healthcare Stocks: Myomo (MYO), Cardiff Oncology (CRDF)
TIPRANKS  ·  2025-11-10
Analysts Are Bullish on These Healthcare Stocks: Myomo (MYO), Cardiff Oncology (CRDF)
Cardiff Oncology posts smaller-than-expected Q3 loss
Reuters  ·  2025-11-07
Cardiff Oncology posts smaller-than-expected Q3 loss
Cardiff Oncology Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $120.000K Beat $112.500K Estimate
Benzinga  ·  2025-11-07
Cardiff Oncology Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $120.000K Beat $112.500K Estimate
Cardiff Oncology Inc expected to post a loss of 20 cents a share - Earnings Preview
Reuters  ·  2025-11-04
Cardiff Oncology Inc expected to post a loss of 20 cents a share - Earnings Preview
Cardiff Oncology Inc. to Participate in H.C. Wainwright Global Investment Conference with CEO Mark Erlander Presenting
Reuters  ·  2025-08-29
Cardiff Oncology Inc. to Participate in H.C. Wainwright Global Investment Conference with CEO Mark Erlander Presenting
BRIEF-Cardiff Oncology Announces Positive Data From Ongoing Randomized Phase 2 First-Line Ras-Mutated Mcrc Clinical Trial (Crdf-004)
Reuters  ·  2025-07-30
BRIEF-Cardiff Oncology Announces Positive Data From Ongoing Randomized Phase 2 First-Line Ras-Mutated Mcrc Clinical Trial (Crdf-004)
Cardiff Oncology Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $121.00K Beat $92.86K Estimate
Benzinga  ·  2025-07-30
Cardiff Oncology Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $121.00K Beat $92.86K Estimate
Cardiff Oncology Inc - Trial Shows 49% Orr in 30Mg Onvansertib Dose Arm
THOMSON REUTERS  ·  2025-07-30
Cardiff Oncology Inc - Trial Shows 49% Orr in 30Mg Onvansertib Dose Arm
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
GlobeNewswire  ·  2025-07-30
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
Cardiff Oncology Inc - Has $71 Mln Cash as of June 30, Runway Into Q1 2027
THOMSON REUTERS  ·  2025-07-30
Cardiff Oncology Inc - Has $71 Mln Cash as of June 30, Runway Into Q1 2027
Cardiff Oncology Inc - Completes Enrollment in Phase 2 Crdf-004 Trial
THOMSON REUTERS  ·  2025-07-30
Cardiff Oncology Inc - Completes Enrollment in Phase 2 Crdf-004 Trial
Cardiff Oncology Inc. Files Initial Statement of Beneficial Ownership for Roger Sidhu, Chief Medical Officer
Reuters  ·  2025-07-09
Cardiff Oncology Inc. Files Initial Statement of Beneficial Ownership for Roger Sidhu, Chief Medical Officer
Cardiff Oncology Initiated at Buy by Ladenburg Thalmann
Dow Jones  ·  2025-07-09
Cardiff Oncology Initiated at Buy by Ladenburg Thalmann
ADVISORY-Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Reuters  ·  2025-07-08
ADVISORY-Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Cardiff Oncology Inc. Concluded Annual Stockholders Meeting
Reuters  ·  2025-06-27
Cardiff Oncology Inc. Concluded Annual Stockholders Meeting

Introduction

Company Name.
Cardiff Oncology, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Issue price:
--